A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
Clinical Trial Grant
Awarded By
GlaxoSmithKline LLC
Start Date
February 23, 2026
End Date
February 28, 2031
Awarded By
GlaxoSmithKline LLC
Start Date
February 23, 2026
End Date
February 28, 2031